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FranceThere is an urgent need to share expertise and offer
emergency guidance for breast radiation therapy (RT) dur-
ing the COVID-19 (Coronavirus) pandemic. As per theWorld
Health Organisation (WHO) statement, our aim and obli-
gation should be “to stop, contain, control, delay and reduce
the impact of this virus at every opportunity”. In our roles as
healthcare professionals and/or breast cancer experts this
translates to minimising exposure of our patients to COVID-
19 without compromising oncological outcome.
It is imperative that hospital visits are kept to the absolute
minimum and that the complexity of RT planning/treatmentAuthor for correspondence: Charlotte E Coles, National Institute of
Health Research (NIHR) Research Professor, Oncology Department, Univer-
sity of Cambridge, Hills Road, Cambridge, CB2 0QQ, UK.
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Given that breast RT accounts for 30 per cent of delivered RT
fractions, the following recommendations require particularly
urgent consideration. By adopting these recommendations
where RT isminimised and targeted to thosewith the highest
risk of relevant breast recurrence, we aim to protect our pa-
tients and health care professionals from potential exposure
to COVID-19 as well as reducing the workload for health care
providers and/or infrastructure at themoments that resources
face strain due to the pandemic. A general guiding principle in
this unusual setting is that: (i) where clinical equipoise has
been sufficient to support the conduct of randomised trials
testing a less resource-intensive approach, and (ii) results
available to date have not provided evidence that such a test
arm is clearly inferior, then (iii) the approach involving fewestAll rights reserved.
C.E. Coles et al. / Clinical Oncology 32 (2020) 279e281280patient visits and duration should be encouraged in the
context of a pandemic like COVID-19 even when level 1e2
evidence has not formally been delivered.
We suggest that the following guidelines are considered
and the risks and benefits are discussed with patients to
facilitate shared decision-making. Centres may need/
choose to delay RT depending on local circumstances with
reference to expert consensus following previous natural
disasters [1] and also amend current systemic therapy
pathways, but this is outside the remit of these guidelines.
1. Omit RT for patients 65 years and over (or younger
with relevant co-morbidities) with invasive breast
cancer that are up to 30mm with clear margins,
grade 1e2, oestrogen receptor (ER) positive, hu-
man epidermal growth factor receptor 2 (HER2)
negative and node negative who are planned for
treatment with endocrine therapy [2].
Trials investigating safe omission of RT can be considered
if they do not impact on patients visits and resources are
available. Centres may also consider omitting RT for
ductal carcinoma in-situ (DCIS) depending on individual
risk and benefit.
2. Deliver RT in 5 fractions only for all patients
requiring RT with node negative tumours that do
not require a boost. Options include 28e30Gy in
once weekly fractions over 5 weeks or 26Gy in 5
daily fractions over 1 week as per the FAST and
FAST Forward trials respectively [3e5].
N.B. 5-year local relapse data are not yet available for
FAST Forward but imminent publication is anticipated. In
the meantime, 26Gy in 5 fractions has already been
demonstrated to be equivalent with 40 Gy in 15 fractions
with respect to 3-year normal tissue outcome. Further-
more, local control is likely to be within acceptable limits
given the low local relapse rates in this patient group
generally [6]. The FAST Forward protocol and RT plan-
ning pack are available at:
https://www.icr.ac.uk/our-research/centres-and-
collaborations/centres-at-the-icr/clinical-trials-and-
statistics-unit/clinical-trials/fast_forward_page/
Partial breast RT using 28.5-6Gy in 5 fractions over 1e2
weeks [7,8] can also be considered for selected patients if
resources are available for increased complexity and/or
to avoid deep inspiration breath hold (DIBH) for left-
sided tumours in the upper half of the breast (if DIBH
impacts on treatment time). N.B. IMPORT Low [6] has the
same fractionation schedule in the control group as FAST
Forward so 26Gy in 5 fractions over 1 week could also be
proposed in the partial breast irradiation setting.
3. Boost RT should be omitted to reduce fractions
and/or complexity in the vast majority of patients
unless they 40 years old and under, or over 40 years
with significant risk factors for local relapse [9].Boost RT has no proven survival advantage so risks and
benefits during the COVID-19 pandemic need to be re-
evaluated. An example of a significant risk factor is the
presence of involved resection margins where further
surgery is not possible. Any boost should be either
simultaneous and integrated to minimise fractions if
resource permits or hypofractionated sequential, e.g.
12Gy in 4 fraction over 4 days.
4. Nodal RT can be omitted in post-menopausal
women requiring whole breast RT following
sentinel lymph node biopsy and primary surgery
for T1, ER positive, HER2 negative G1-2 tumours
with 1e2 macrometastases [10].
This approach gives this group of patients the option of 5
fractions of RT, and may reduce complexity of planning/
treatment.
5. Moderate hypofractionation should be used for all
breast/chest wall and nodal RT, e.g. 40Gy in 15
fractions over 3 weeks [11e14].
The use of moderate hypofractionation is already the
standard of care inmany countries and in the altered risk-
benefit context of a pandemic should be strongly consid-
ered in patients with breast reconstruction. However,
many centres will halt immediate reconstruction during
the pandemic as this is not essential cancer surgery.
References
[1] Gay HA, Santiago R, Gil B, Remedios C, Montes PJ, Lopez-
Araujo J, et al. 3rd lessons learned from hurricane maria in
puerto rico: practical measures to mitigate the impact of a
catastrophic natural disaster on radiation oncology patients.
Pract Radiat Oncol 2019 Sep - Oct;9(5):305e321.
[2] Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM.
PRIME II investigators. Breast-conserving surgery with or
without irradiationin women aged 65 years or older with
early breast cancer (PRIME II): a randomised controlled trial.
Lancet Oncol 2015 Mar;16(3):266e273. https://doi.org/10.
1016/S1470-2045(14)71221-5.
[3] Brunt AM, Haviland J, Sydenham M, Algurafi H, Alhasso A,
Bliss P, et al. FAST Phase III RCT of Radiotherapy Hypofractio-
nation for Treatment of Early Breast Cancer: 10-Year Results
(CRUKE/04/015). IJROBP 2018;102(5):1603e1604.
[4] Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S,
Harnett A, et al. FAST-Forward Trial Management Group.
Acute skin toxicity associated with a 1-week schedule of
whole breast radiotherapy compared with a standard 3-week
regimen delivered in the UK FAST-Forward Trial. Radiother
Oncol 2016;120:114e118.
[5] Brunt AM, Haviland JS, Sydenham MA, Alhasso A,
Bloomfield D, Chan C, et al. OC-0595: FAST-Forward phase 3
RCT of 1-week hypofractionated breast radiotherapy: 3-year
normal tissue effects. Radiother Oncol April 2018;127(Sup-
plement 1):S311eS312.
[6] Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A,
et al. IMPORT Trialists. Partial-breast radiotherapy after breast
conservation surgery for patients with early breast cancer (UK
C.E. Coles et al. / Clinical Oncology 32 (2020) 279e281 281IMPORT LOW trial): 5-year results from a multicentre, rand-
omised, controlled, phase 3, non-inferiority trial. Lancet 2017
Sep 9;390(10099):1048e1060.
[7] Livi L, Meattini I, Marrazzo L, Simontacchi G, Pallotta S,
Saieva C, et al. Accelerated partial breast irradiation using
intensity-modulated radiotherapy versus whole breast irra-
diation: 5-year survival analysis of a phase 3 randomised
controlled trial. Eur J Cancer 2015 Mar;51(4):451e463.
[8] First results of the preoperative accelerated partial breast
irradiation (PAPBI) trialvan der Leij F, Bosma SC, van de
Vijver MJ, Wesseling J, Vreeswijk S, Rivera S, et al. First results
of the post-operative accelerated partial breast irradiation
(PAPBI) trial. Radiother Oncol 2015 Mar;114(3):322e327.
[9] Bartelink H, Maingon P, Poortmans P, Weltens C, Fourquet A,
Jager J, et al. European Organisation for Research and Treat-
ment of Cancer Radiation Oncology and Breast Cancer Groups.
Whole-breast irradiation with or without a boost for patients
treated with breast-conserving surgery for early breast can-
cer: 20-year follow-up of a randomised phase 3 trial. Lancet
Oncol 2015 Jan;16(1):47e56. https://doi.org/10.1016/S1470-
2045(14)71156-8.[10] Bloomfield DJ. Core Group facilitated by The Royal College of
Radiologists. Development of postoperative radiotherapy for
breast cancer: UK consensus statements e a model of patient,
clinical and commissioner engagement? Clin Oncol R Coll
Radiol 2017 Oct;29(10):639e641.
[11] Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-
Lee PJ, et al, START Trialists’ Group. The UK standardisation of
breast radiotherapy (START) trials of radiotherapy hypo-
fractionation for treatment of early breast cancer: 10-year
follow-up results of two randomised controlled trials. Lancet
Oncol 2013 Oct;14(11):1086e1094.
[12] https://www.nice.org.uk/guidance/ng101.
[13] Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R,
Parpia S, et al. Long-term results of hypofractionated radiation
therapy for breast cancer. N Engl J Med 2010 Feb 11;362(6):
513e520.
[14] Leong N, Truong PT, Tankel K, Kwan W, Weir L, Olivotto IA.
Hypofractionated nodal radiation therapy was not associated
with increased patient-reported arm or brachial plexopathy
symptoms. Int J Radiat Oncol Biol Phys 2017 Dec 1;99(5):
1166e1172.
